Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Peripheral Vascular Disease
Would you consider a short duration of dual antiplatelet therapy following plain old balloon angioplasty (POBA) to a femoropopliteal bypass graft
If so, what is a reasonable duration of therapy?
Answer from: at Community Practice
Aspirin alone is sufficient after plain old balloon angioplasty, particularly in a high bleeding risk patient.
Sign In
or
Register
to read more
28961
Related Questions
Would you favor additional work-up for abnormally elevated ABIs that suggest noncompressible vessels to confirm the presence of PAD?
How do you evaluate the etiology of worsening limb ischemia between progression of known PAD or cardioembolic disease?
How long do you continue aspirin and clopidogrel after and uncomplicated transfemoral carotid stent?
Would the diagnostic yield for ABIs or peripheral arterial duplex doppler in a patient with metal rods in both legs be similar or acceptable in comparison to those tests in a patient without metal rods?
Do you prioritize prescribing semaglutide in patients with type 2 diabetes and peripheral arterial disease, given trial data demonstrating improved maximum walking distance with its use?
Which type of patients with asymptomatic peripheral arterial disease with an ABI score of less than 0.9, is it reasonable to offer antiplatelet and statin therapy to?
How do you recommend mitigating the risks of using beta blocker and clonidine therapy in combination for management of hypertension?
What are your preferred echocardiographic parameters and goals for weaning RVAD support?
How do you use NT-proBNP in patients with chronic kidney disease or end-stage kidney disease, given that these conditions can affect NT-proBNP levels?
How are you incorporating the newer RCT data suggesting no mortality benefit to indefinite beta-blocker therapy for patients who are several years out from an MI with preserved LVEF and no angina or arrhythmia?